Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antibiotic-impregnated calcium sulfate is a biodegradable biomaterial intervention being studied by the University of Washington for the treatment of open tibia fractures with sub-segmental bone loss. It consists of calcium sulfate (CaSO4) mixed with antibiotics to form a spacer that is implanted directly into bone defects. The material acts as an osteoconductive scaffold, providing a structure for new bone growth while simultaneously delivering high concentrations of antibiotics locally to prevent or treat infection. Unlike traditional PMMA (polymethylmethacrylate) spacers, calcium sulfate is resorbable, meaning it is gradually broken down and replaced by host bone, which may eliminate the need for a secondary surgical procedure to remove the spacer. This intervention is currently being evaluated in a Phase 4 clinical trial (NCT03042546) to determine its efficacy in preventing nonunion and reducing the need for additional surgeries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antibiotic-impregnated calcium sulfate.